Zacks.com on MSN
GSK Gets EU Approval for Expanded Use of Nucala in COPD
GSK plc GSK announced that the European Commission has approved its blockbuster respiratory drug, Nucala (mepolizumab), for ...
Dupilumab, a simple pre-filled pen that people inject themselves with every two weeks, is the first biologic that targets both the symptoms of COPD and an underlying cause of the disease. It brings ...
Stopping long-acting inhalers for chronic obstructive pulmonary disease (COPD) can lead to a sharp rise in flare-ups for ...
NICE has recommended dupilumab for adults with uncontrolled COPD and raised eosinophils, citing fewer exacerbations and ...
A biologic injection that reduces chronic obstructive pulmonary disease (COPD) flare-ups by around a third has been approved for use on the NHS in England and Wales. The National Institute for Health ...
Novel, experimental treatment for emphysema may offer promising results for patients looking to breathe easier ...
NICE has approved the first targeted treatment for chronic obstructive pulmonary disease (COPD), offering a new option to up ...
The National Institute for Health and Care Excellence (NICE), has published final draft guidance recommending dupilumab as a ...
Almost 30,000 people in England with COPD (chronic obstructive pulmonary disease) could have their lives transformed after the National Institute for Health and Care Excellence recommended a new ...
When appropriate, surgery remains the most effective treatment option for non-small cell lung cancer (NSCLC), including for patients with COPD, said Friedberg, professor in the Department of Thoracic ...
GSK (GSK) stock is in focus as the company wins EU approval to expand its Nucala asthma drug into chronic obstructive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results